Efficacy of denosumab with regard to bone destruction in prognostic subgroups of Japanese rheumatoid arthritis patients from the phase II DRIVE study.

ABSTRACT:

Objectives

To evaluate the efficacy of denosumab for progressive bone erosion in risk factor subgroups of Japanese RA patients.

Methods

This study included 340 RA patients on MTX from the dose-response study of Denosumab in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE study-a 12-month, multicentre, randomized, double-blind, placebo-controlled, phase II study). The patients were randomized to receive placebo or denosumab 60 mg every 6 months, 3 months or 2 months. Subgroup analyses involved baseline RF, ACPA, swollen joint count, CRP level, RA duration, ESR and glucocorticoid use.

Results

Patients with risk factor positivity generally showed consistent results for the primary endpoint of the change in the modif

SUBMITTER: Ishiguro N 

PROVIDER: S-EPMC6532444 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature